Minghong Zhong

Minghong Zhong began their career in 2015 as a Principal Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson, where they were responsible for designing and developing a solution phase synthesis platform for oligonucleotides and their conjugates, as well as acting as project leader and chemistry leader for the design, synthesis, and development of nucleosides, nucleotides, and their prodrugs. In 2021, they joined GeneLancet Biosciences, Inc. as their Chief Scientific Officer, where they managed and led the company's R&D and part of its daily operations. Minghong also set up and ran an oligonucleotide chemistry/biochemistry lab and improved GeneLancet's patented chemically-ligated CRISPR-Cas9 single-molecule guide RNA (lgRNA) platform technology, leading to ultra-pure full-length products with significantly improved product quality.

Minghong Zhong completed a Postdoctoral Research at Yale University School of Medicine in Molecular biophysics & Biochemistry from 2004 to 2007. Minghong then obtained a Doctor of Philosophy (Ph.D.) from Brigham Young University in Organic Chemistry/Nucleic Acid Chemistry. Currently, they are pursuing two Certificates from Montgomery College: Advanced Gene Editing With CRISPR, Bio-Trac Training Program and Gene Editing With CRISPR, Bio-Trac Training Program.